Indications for: COMIRNATY
Active immunization to prevent COVID-19 in individuals ≥16yrs of age.
Give by IM inj only. ≥16yrs: 0.3mL given as a 2-dose series 3 weeks apart.
<16yrs: not established.
Have epinephrine inj available. Increased risks of myocarditis and pericarditis (esp. within 7 days after the second dose); higher risk among males <40yrs of age, and highest among males 12–17yrs of age. Syncope. Immunocompromised. Pregnancy. Nursing mothers.
Immunosuppressants: may get suboptimal response.
Inj site reactions (eg, pain, swelling, redness), fatigue, headache, muscle pain, chills, joint pain, fever.
Generic Drug Availability:
Multiple-dose vials—25, 195 (w. diluent; shipped separately)